APA (7th ed.) Citation

B, C., N, B., JM, M., D, C., JC, G., A, L., . . . groups, P. 1. a. 2. s. (2007). Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet, 369(9568), 1169. https://doi.org/10.1016/s0140-6736(07)60497-8

Chicago Style (17th ed.) Citation

B, Clotet, et al. "Efficacy and Safety of Darunavir-ritonavir at Week 48 in Treatment-experienced Patients with HIV-1 Infection in POWER 1 and 2: A Pooled Subgroup Analysis of Data from Two Randomised Trials." Lancet 369, no. 9568 (2007): 1169. https://doi.org/10.1016/s0140-6736(07)60497-8.

MLA (9th ed.) Citation

B, Clotet, et al. "Efficacy and Safety of Darunavir-ritonavir at Week 48 in Treatment-experienced Patients with HIV-1 Infection in POWER 1 and 2: A Pooled Subgroup Analysis of Data from Two Randomised Trials." Lancet, vol. 369, no. 9568, 2007, p. 1169, https://doi.org/10.1016/s0140-6736(07)60497-8.